Oral Steroid Gets FDA Approval for IgA Nephropathy Oral Steroid Gets FDA Approval for IgA Nephropathy

Oral budesonide delayed-release (Tarpeyo) became the first agent to receive FDA approval for reducing proteinuria in patients with primary IgA nephropathy and at risk for rapid progression.FDA Approvals
Source: Medscape Pharmacist Headlines - Category: Drugs & Pharmacology Tags: Nephrology News Alert Source Type: news